CPP
SRNE

Crow Point Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Crow Point Partners’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-44,565
Closed -$76K – 294
2017
Q3 		$76K Sell
44,565
-52,971
-54% -$97.2K 0.01% 195
2017
Q2 		$200K Buy
+97,536
New +$190K 0.03% 128

Other funds holding SRNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Crow Point Partners's SRNE Position: Q4 2017 in Review

Crow Point Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2017, closing a stake of 44,565 shares — an estimated $76K sold.

Crow Point Partners first reported a position in SRNE in Q2 2017 and held it in 2 quarters. The position peaked at $200K in Q2 2017. 46 funds tracked by Wall St. Rank hold SRNE as of Q4 2017.

  • Crow Point Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Crow Point Partners sold 44,565 Sorrento Therapeutics, Inc. shares in Q4 2017, an estimated $76K.
  • Crow Point Partners first reported a position in Sorrento Therapeutics, Inc. in Q2 2017 and held it in 2 quarters.
  • Crow Point Partners's Sorrento Therapeutics, Inc. position peaked at $200K in Q2 2017.
  • 46 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2017.

Based on Crow Point Partners's 13F filing for Q4 2017, filed 10 Jan 2018.